Author Topic: (Abst.) 2-year results from phase 2 extension study of oral amiselimod in RRMS  (Read 92 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9542
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal, September 15, 2017:

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, ...


Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis.


To assess safety and efficacy of amiselimod over 96 weeks.


After completing the core study, patients on amiselimod continued at the same dose, whereas those on placebo were randomised 1:1:1 to amiselimod 0.1, 0.2 or 0.4 mg for another 72 weeks. Most patients receiving 0.1 mg were re-randomised to 0.2 or 0.4 mg upon availability of the core study results.


Of 415 patients randomised in the core study, 367 (88.4%) entered and 322 (77.6%) completed the extension. One or more adverse events were reported in 303 (82.6%) of 367 patients: ‘headache’, ‘lymphocyte count decreased’, ‘nasopharyngitis’ and ‘MS relapse’ were most common (14.7%–16.9%). No serious opportunistic infection, macular oedema or malignancy was reported and no bradyarrhythmia of clinical concern was observed by Holter or 12-lead electrocardiogram. The dose-dependent effect of amiselimod on clinical and magnetic resonance imaging-related outcomes from the core study was sustained in those continuing on amiselimod and similarly observed after switching to active drug.


For up to 2 years of treatment, amiselimod was well tolerated and dose-dependently effective in controlling disease activity.

The abstract, along with more information on the authors, can be seen here.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post September 17, 2016, 06:43:41 am
by agate
0 Replies
Last post October 13, 2016, 05:53:43 am
by agate
2 Replies
Last post June 18, 2017, 04:06:52 pm
by agate
0 Replies
Last post February 01, 2019, 09:40:35 pm
by agate
0 Replies
Last post December 02, 2020, 03:35:02 pm
by agate